MAbs targeting TIM-3 (TSR-022) and KIR (lirilumab) proteins, produced from in vitro somatic hypermutation of a library of human germ lines and from humanized transgenic mice, respectively, are currently being evaluated in early stage clinical trials as anti-ICI therapeutics to treat various cancers [14, 15]. Here, HAVCR2 is linked to cancer.